glp-1 weight loss drug marketplace florida changes 2025 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of medications like semaglutide and tirzepatide, signaling a major shift in how these Alarming rise in weight loss

Last week, Eli Lillys orforglipron became the first oral small molecule GLP-1 receptor agonist to clear a Phase 3 trial (ACHIEVE-1) no peptides, no injections, no cold chain

40 GLP-1RA can also influence hepatic stellate cell activation and extracellular matrix adjustment

GLP-1R agonists can improve left ventricular ejection fraction, myocardial contractility, coronary blood flow, cardiac output, and endothelial function while reducing infarction size and overall risks for a cardiovascular event

Semaglutide targets one receptor (GLP-1), while tirzepatide targets two (GIP + GLP-1)

They are all wonderful

Research published in The Lancet examining GLP-1 receptor agonist eligibility across 99 countries found that eligibility varies dramatically based on which BMI thresholds are used